| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
A majority of physicians believe medicine is on the verge of groundbreaking new treatments for Alzheimer's disease, according to research from Quest Diagnostics.
While value-based care contracts have long played a role in the lab industry, recent comments by Quest Diagnostics executives suggest that such arrangements are growing more prominent and more profitable.
As millions of U.S. employees voluntarily resign and employers desperately scramble to find workers, a new survey suggests employee health strategy might be critical not only to keeping employees well but also keeping them at work. The “2022 Health at Work” report, released by Quest Diagnostics, addresses such hot-button topics as the changing world of work, employee health, and COVID-19.
Digital pathology is here to stay – and we need to embrace it. About the Author: Martin Potash is Managing Director of AmeriPath Denver, Quest Diagnostics, Colorado, USA.
Testing giant Quest Diagnostics is diving into the market for blood tests that aid in the early detection of Alzheimer’s disease. The disease afflicts millions of people around the world. But early detection typically relies on costly methods such as brain imaging and cerebrospinal fluid taps. Blood tests like the one developed by Quest promise to make detection easier, less costly and more accessible.